Loading patent…
AssigneeSmc Global Asset, Inc.
InventorHirofumi TAKANO
Estimating the term…
The present invention provides a model animal for establishing an effective therapy for a protein aggregation disease typified by Alzheimer's disease and the like. More specifically, the present invention provides the followings: (A) a non-human animal that exhibits a degenerative symptom attributed to protein aggregation, wherein the degenerative symptom attributed to protein aggregation is induced by misfolding of the protein and said degenerative symptom is promoted; and (B) a method for producing the non-human animal that exhibits the degenerative symptom attributed to the protein aggregation, comprising the following (1) and (2): (1) inducing misfolding of the protein to cause the degenerative symptom attributed to the protein aggregation in the non-human animal, and (2) giving a treatment to promote the degenerative symptom attributed to the protein aggregation in the non-human animal.
A non-human animal that exhibits a degenerative symptom attributed to protein aggregation, wherein the degenerative symptom attributed to the protein aggregation is induced by misfolding of the protein and said degenerative symptom is promoted.
A method for producing a non-human animal that exhibits a degenerative symptom attributed to protein aggregation, comprising the following (1) and (2):
A non-human animal that exhibits a degenerative symptom attributed to protein aggregation, and to which 2-amino-1-methyl-6-phenyl-1H-imidazo[4,5-b] pyridine is administered.
A method for producing a non-human animal that exhibits a degenerative symptom attributed to protein aggregation, comprising administering 2-amino-1-methyl-6-phenyl-1H-imidazo[4,5-b] pyridine.
Dependencies are inferred from the claim text.